Page last updated: 2024-11-11

khafrefungin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

khafrefungin: inhibits inositol phosphoceramide synthase in fungi; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9851575
CHEMBL ID1631582
MeSH IDM0284714

Synonyms (5)

Synonym
bdbm50333121
khafrefungin
CHEMBL1631582 ,
(2s,3s,4r)-2,3,5-trihydroxy-4-[(2e,4r,6e,8e,10s,11r,12s)-11-hydroxy-2,4,6,8,10,12-hexamethyl-5-oxodocosa-2,6,8-trienoyl]oxypentanoic acid
Q58049114

Research Excerpts

Overview

Khafrefungin is an antifungal agent. It inhibits inositol phosphorylceramide (IPC) synthase, an enzyme involved in fungal sphingolipid biosynthesis.

ExcerptReferenceRelevance
"Khafrefungin is an antifungal agent that inhibits inositol phosphorylceramide (IPC) synthase, an enzyme involved in fungal sphingolipid biosynthesis."( Chemistry and biology of khafrefungin. Large-scale synthesis, design, and structure-activity relationship of khafrefungin, an antifungal agent.
Hanada, K; Kobayashi, S; Mori, Y; Nakamura, M; Okuyama, K; Tanikawa, K; Yasuda, S, 2003
)
1.34

Actions

ExcerptReferenceRelevance
"Khafrefungin does not inhibit the synthesis of mammalian sphingolipids thus making this the first reported compound that is specific for the fungal pathway."( Khafrefungin, a novel inhibitor of sphingolipid synthesis.
Bull, HG; Garcia-Calvo, M; Kurtz, MB; Mandala, SM; Milligan, J; Rosenbach, M; Thornton, RA, 1997
)
2.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Inositol phosphorylceramide synthaseCandida albicans SC5314IC50 (µMol)0.00060.00020.00040.0006AID542410
Inositol phosphorylceramide synthaseCandida albicans SC5314Ki0.00040.00020.00040.0005AID542405
Inositol phosphorylceramide synthase catalytic subunit AUR1Saccharomyces cerevisiae S288CIC50 (µMol)5.67150.00020.02160.0430AID542406; AID542407
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID542410Inhibition of Candida albicans inositol phosphorylceramide synthase2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID542404Inhibition of Candida albicans ATCC 38247 inositol phosphorylceramide synthase2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID542406Inhibition of Saccharomyces cerevisiae SJ21R inositol phosphorylceramide synthase preincubated for 30 mins2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID542405Inhibition of Candida albicans ATCC 38247 inositol phosphorylceramide synthase preincubated for 30 mins2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID542407Inhibition of aureobasidin A-resistant Saccharomyces cerevisiae inositol phosphorylceramide synthase preincubated for 30 mins2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's8 (80.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (18.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]